<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; eclectic</title>
	<atom:link href="http://www.tapanray.in/tag/eclectic/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Being Eclectic – A Pharma Leadership Quality In The New Normal</title>
		<link>http://www.tapanray.in/being-eclectic-a-pharma-leadership-quality-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=being-eclectic-a-pharma-leadership-quality-in-the-new-normal</link>
		<comments>http://www.tapanray.in/being-eclectic-a-pharma-leadership-quality-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 21 Jun 2021 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[eclectic]]></category>
		<category><![CDATA[gamification]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10531</guid>
		<description><![CDATA[It’s no-brainer that since the onset of Covid pandemic, digitalization initiative of many pharma companies in critical facets of business operations, has reached a new high. The process is now fast accelerating with the adoption of avant-garde ideas, and scalable &#8230; <a href="http://www.tapanray.in/being-eclectic-a-pharma-leadership-quality-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/being-eclectic-a-pharma-leadership-quality-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Pricing: Why Justify On R&amp;D Cost Rather Than Precise ‘Customer Value’?</title>
		<link>http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value</link>
		<comments>http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/#comments</comments>
		<pubDate>Mon, 16 Dec 2019 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[connects]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[eclectic]]></category>
		<category><![CDATA[electronics]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[justification]]></category>
		<category><![CDATA[justify]]></category>
		<category><![CDATA[lawsuit]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[monetary]]></category>
		<category><![CDATA[offerings]]></category>
		<category><![CDATA[Oregon]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9815</guid>
		<description><![CDATA[While looking around, it won’t be difficult to spot many types of steep-priced highly innovative products, where high costs aren’t justified by high R&#38;D expenditure, but for unique ‘customer value’ offerings. Many consumers evaluate those and decide to settle for &#8230; <a href="http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma R&amp;D: Chasing A Rainbow To Replicate The Past</title>
		<link>http://www.tapanray.in/pharma-rd-chasing-a-rainbow-to-replicate-the-past/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-rd-chasing-a-rainbow-to-replicate-the-past</link>
		<comments>http://www.tapanray.in/pharma-rd-chasing-a-rainbow-to-replicate-the-past/#comments</comments>
		<pubDate>Mon, 25 Jan 2016 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Deloitte]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[eclectic]]></category>
		<category><![CDATA[exorbitant]]></category>
		<category><![CDATA[external]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Harmoni]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Nucala]]></category>
		<category><![CDATA[past]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rainbow]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[replicate]]></category>
		<category><![CDATA[return]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Treshba]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7405</guid>
		<description><![CDATA[Would future be always a replica of the past? If the response is yes, the efforts of many global pharma players to replicate the successful Research and Development (R&#38;D) models of long gone by days, would continue to be a &#8230; <a href="http://www.tapanray.in/pharma-rd-chasing-a-rainbow-to-replicate-the-past/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-rd-chasing-a-rainbow-to-replicate-the-past/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Leading Through The Challenge Of Change: Is Pharma Leadership Too Archaic?</title>
		<link>http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic</link>
		<comments>http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/#comments</comments>
		<pubDate>Mon, 16 Jun 2014 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[archaic]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[eclectic]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[inclusive]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Michael]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[Motors]]></category>
		<category><![CDATA[Ostrich]]></category>
		<category><![CDATA[owner]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[promoter]]></category>
		<category><![CDATA[prontosil]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Rsy]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Soman.]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tesla]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5512</guid>
		<description><![CDATA[A recent major global survey titled “Testing The Health Of The Pharmaceutical Industry” has revealed that a sizable majority of executives polled, though believe the sector is in good shape, are concerned of its reputation. Interestingly, 73 percent of respondents believe &#8230; <a href="http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
